Second-line chemotherapy for small-Cell Lung Cancer (SCLC)

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

2006 • 1,745 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

2006 • 603 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

1992 • 532 citations

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

2009 • 507 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

2007 • 356 citations

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

2008 • 236 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

2006 • 227 citations

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

2009 • 195 citations

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.

1985 • 188 citations

Phase II study of imatinib in patients with small cell lung cancer.

2003 • 180 citations

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

1995 • 178 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1987 • 155 citations

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

2005 • 154 citations

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

2005 • 148 citations

Small cell lung carcinoma (SCLC): the angiogenic phenomenon

2002 • 136 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

1988 • 131 citations

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

2010 • 124 citations

Reinduction chemotherapy in small cell lung cancer

1987 • 121 citations

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

1999 • 114 citations

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

2006 • 110 citations

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

1998 • 101 citations

Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells

1998 • 100 citations

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial

2006 • 94 citations

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

2004 • 89 citations

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

2009 • 85 citations

Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts

1989 • 83 citations

Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective

2008 • 74 citations

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1998 • 72 citations

Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

1986 • 72 citations

Small cell lung cancer

2006 • 72 citations

VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

1984 • 68 citations

Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer

2001 • 68 citations

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens

2003 • 67 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

2003 • 61 citations

Anti‐tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts

1997 • 60 citations

Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update

2004 • 58 citations

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin

1997 • 55 citations

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

2009 • 53 citations

Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer

2002 • 53 citations

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study

2001 • 49 citations

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

2006 • 48 citations

Second-line chemotherapy for relapsed small cell lung cancer

1997 • 47 citations

Recurrent small cell lung cancer: Update

2003 • 46 citations

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer

2003 • 45 citations

Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)

2006 • 40 citations

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902

2006 • 39 citations

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.

1997 • 38 citations

Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

1986 • 37 citations

Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer

2003 • 35 citations

Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer

2007 • 35 citations

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

2008 • 34 citations

Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer

2000 • 33 citations

Single agent oral topotecan (OT) as first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: A phase II study

2000 • 33 citations

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

2004 • 32 citations

Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.

1995 • 32 citations

Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer

2005 • 31 citations

A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer

2008 • 31 citations

A Phase II Study of Topotecan in Patients with Relapsed Small-Cell Lung Cancer

2003 • 30 citations

Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study

2009 • 29 citations

Toxicological Aspects of a Novel 9‐Aminoanthracycline, SM‐5887

1989 • 29 citations

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group

1993 • 29 citations

Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer

1988 • 28 citations

Phase II Trial of Gemcitabine/Irinotecan in Refractory or Relapsed Small-Cell Lung Cancer

2005 • 28 citations

Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): A SWOG (S0435) phase II trial

2008 • 28 citations

Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: A southeastern cancer study group trial

1987 • 28 citations

Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer

2000 • 28 citations

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

2008 • 26 citations

Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097)

2008 • 26 citations

Combination Chemotherapy with Irinotecan and Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A Phase II Study

2003 • 25 citations

Treatment of relapsed small cell lung cancer

2001 • 23 citations

Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer

1990 • 20 citations

A phase II randomised trial comparing the cisplatin–etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer

2002 • 19 citations

Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer

2006 • 19 citations

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG)

2000 • 18 citations

Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy

2009 • 16 citations

AIDS-Related Kaposi's Sarcoma of the Gastrointestinal Tract

2010 • 15 citations

Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

2005 • 13 citations

Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience.

1992 • 13 citations

Ambamustine in the Second-Line Treatment of Patients With Small-Cell Lung Cancer

2000 • 10 citations

Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group

2008 • 8 citations

Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer

1993 • 8 citations

Phase II study of ACNU as second-line treatment in small-cell lung cancer

1992 • 7 citations

Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update

2009 • 6 citations

Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer

2009 • 6 citations

Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models

2006 • 4 citations

Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC)

2006 • 4 citations